Hypoparathyroidism: an uncommon adverse effect of treatment with durvalumab

SUMMARY: Immune checkpoint inhibitors (ICIs) are monoclonal antibodies approved for the treatment of numerous cancer types. Toxicities induced by ICIs may affect any organ system and manifest as endocrinopathy. The main side effects related to treatment are immune-related adverse events (irAEs), esp...

Descripción completa

Detalles Bibliográficos
Autores principales: Kreze, Alexander, Homer, Matěj, Barešová, Tereza, Klemperová, Kristina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10259288/
https://www.ncbi.nlm.nih.gov/pubmed/37435467
http://dx.doi.org/10.1530/EO-22-0047

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10259288/
https://www.ncbi.nlm.nih.gov/pubmed/37435467
http://dx.doi.org/10.1530/EO-22-0047

Ejemplares similares